if they were looking at that, the SP would be above where it is? Our financials are fantastic. We’re producing free cash flow running multiple trials and Daybue is only in its early stages of growth imo. I don’t see a single profitable ASX company with substantial earnings growth that trades on a severely contracted price to sales, or price to earnings (actual or estimated forward) like NEU does.
edit: a single biotech or health device company *
Share Price, page-10339
-
- There are more pages in this discussion • 2,747 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.03 |
Change
0.700(4.29%) |
Mkt cap ! $2.176B | |||
| Open | High | Low | Value | Volume |
| $16.49 | $17.21 | $16.44 | $11.40M | 677.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4624 | $17.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.05 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |